Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Harvard Bioscience, Inc. (NasdaqNM:HBIO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Reports
Recent Events
Aug 31Price hit new 52-week high ($14.25)
Location
84 October Hill Road
Holliston, MA 01746
Phone: (508) 893-8999
Fax: (508) 429-5732
Email: bioscience@harvardapparatus.com
Employees (last reported count): 131
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Technology
 ·Industry: Scientific & Technical Instr.
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 66%
·Over the last 6 months:
 · 8 insider sells; 1.59M shares
  (8.3% of insider shares)
·Institutional: 36% (107% of float)
(56 institutions)
·Net Inst. Buying: 3.27M shares (+25.26%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Harvard Bioscience, Inc. is a provider of research enabling tools for drug discovery. The Company provides an array of tools designed to accelerate the speed and to reduce the cost at which its customers can introduce new drugs. Since its 1996 reorganization, the Company has focused on alleviating the protein purification and absorption, distribution, metabolism, elimination and toxicology (ADMET) screening bottlenecks in drug discovery. The Company's products consist of both proprietary and non-proprietary products. The Company's Proteomics Products for Protein Purification include protein purification pipette tips, spin columns, protein purification dialyzers and disposable equilibrium dialyzers. Proteomics Products for protein analysis include molecular biology spectrophotometers, DNA/RNA/protein calculators, multi-well plate readers and amino acid analysis systems.
More from Market Guide: Expanded Business Description

Financial Summary
Harvard Bioscience, Inc. provides research-ennabling tools for drug discovery research at pharmaceutical and biotechnology companies, universities and government research laboratories. For the six months ended 6/30/01, revenues rose 27% to $18.3 million. Net loss applicable to Common fell 92% to $5.1 million. Revenues reflect organic growth from acquired product lines. Lower loss reflects the absence of a $67.5 million warrant interest expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Chane Graziano, 62
CEO, Director
$508K$15M
David Green, 36
Pres, Director
455K15M
Susan Luscinski, 44
CFO
163K411K
Mark Norige, 46
COO
155K307K
John House, 56
Managing Director, Biochrom Ltd
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:HBIOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Mar-2001
$5.875
Recent Price$14.20 
52-Week High
on 31-Aug-2001
$14.25 
Daily Volume (3-month avg)310.0K
Daily Volume (10-day avg)189.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change+62.3%
26-Week Change
relative to S&P500
+76.7%
Share-Related Items
Market Capitalization$377.4M
Shares Outstanding26.6M
Float9.00M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.47 
Earnings (ttm)$0.13 
Earnings (mrq)-$0.21 
Sales (ttm)$2.00 
Cash (mrq)$1.18 
Valuation Ratios
Price/Book (mrq)5.74 
Price/Earnings (ttm)106.77 
Price/Sales (ttm)7.09 
Income Statements
Sales (ttm)$34.4M
EBITDA (ttm)-$776.0K
Income available to common (ttm)$11.6M
Profitability
Profit Margin (ttm)33.8%
Operating Margin (ttm)-50.7%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)24.14%
Return on Equity (ttm)30.20%
Financial Strength
Current Ratio (mrq)5.52 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$31.2M
Short Interest
As of 8-Aug-2001
Shares Short38.0K
Percent of Float0.4%
Shares Short
(Prior Month)
63.0K
Short Ratio0.22 
Daily Volume174.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.